GLP-1 Therapies and NAION: What Is the Actual Risk?

GLP-1 therapies have changed the way we treat obesity, type 2 diabetes, and cardiometabolic disease. Medications such as semaglutide, including Ozempic, Wegovy, and Rybelsus, and related incretin-based therapies such as tirzepatide, have helped many patients lose weight, improve glucose control, lower cardiovascular risk, and reduce the burden of metabolic disease.

However, as use has expanded, a rare eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION, has received more attention. The concern is understandable. Any condition that can cause sudden vision loss deserves respect.

At the same time, the discussion needs balance. A rare safety signal should not be dismissed. Yet it also should not be inflated into a reason for every patient to avoid treatment. Crucially, current database signals and regulatory updates specifically center around semaglutide rather than being confirmed as a broad class effect for other incretins like tirzepatide. The real question is more practical: how common is NAION, what symptoms matter, who is at higher risk, and when should someone pause before starting a GLP-1 therapy?

As an endocrinologist, diabetes specialist, and obesity specialist, I view this issue through the broader metabolic context. The eye, blood vessels, glucose levels, blood pressure, sleep apnea, and cholesterol all interact. A meaningful approach looks at the whole patient, not just the medication.

What Is NAION?

NAION occurs when blood flow to the front part of the optic nerve drops enough to injure the nerve. The optic nerve carries visual information from the eye to the brain. When part of that nerve loses circulation, vision can change suddenly.

NAION usually affects one eye. It often occurs without pain. Many patients first notice the problem when they wake up. That timing matters because nighttime blood pressure changes, sleep apnea, vascular disease, and optic nerve anatomy may all play a role.

The classic symptoms include:

• Sudden painless vision loss in one eye
• Blurry, cloudy, dim, or gray vision
• Loss of part of the visual field
• A shadow or dark area in vision
• Reduced contrast or washed-out colors
• Vision loss noticed upon waking

The UK Medicines and Healthcare products Regulatory Agency describes NAION as sudden, painless vision loss, usually in one eye, often experienced as blurring or cloudiness. It advises urgent ophthalmologic evaluation for sudden or partial vision loss during semaglutide treatment.

What Is the Actual Prevalence?

This section needs careful interpretation because headlines often focus on relative risk. Relative risk tells us how much a risk changes compared with another group. Absolute risk tells us how likely the event actually is.

NAION was rare before GLP-1 therapies became popular. Background incidence estimates vary by age and population. In adults over 40 or 50, estimates generally fall in the range of roughly 8–15 cases per 100,000 person-years, while estimates in type 2 diabetes vary more widely, from about 11–82 cases per 100,000 person-years.

The 2024 study that raised much of the concern came from a single academic neuro-ophthalmology center. It found a higher cumulative incidence of NAION among patients prescribed semaglutide compared with patients using non-GLP-1 therapies. In patients with type 2 diabetes, the 36-month cumulative incidence was 9% with semaglutide vs 2% with non-GLP-1 medications. In patients treated for overweight or obesity, it was 7% vs 1%.

Those numbers sound high, but they should not be read as the everyday prevalence for all GLP-1 users. The study population came from a neuro-ophthalmology setting, where eye disease naturally appears more often than in the general prescribing population. The authors also noted that the study showed an association, not proof that semaglutide caused NAION.

A later large multicenter study found a more modest signal. In that study, the incidence rate of NAION among new semaglutide users with type 2 diabetes was 14.5 per 100,000 person-years. The authors concluded that semaglutide use was associated with a modest increase in NAION risk, smaller than earlier reports, and that the issue needed further study. Longer-term database tracking also indicates that this risk is not a transient, short-term hazard during initiation; the statistical divergence can continue to emerge over a two- to four-year timeline.

European and UK regulators have described NAION with semaglutide as very rare. The European review estimated about a two-fold relative increase in adults with type 2 diabetes, corresponding to about one additional case per 10,000 treated people per year.

So, the practical answer is this: NAION may be associated with semaglutide, but it appears very rare in absolute terms. The signal deserves attention, especially in higher-risk patients, but it does not mean NAION is common among people using GLP-1 therapy.

Who Is at Higher Risk?

NAION does not usually happen because of one factor alone. It often develops when several vulnerabilities converge: vascular risk, optic nerve anatomy, nighttime blood pressure patterns, and sometimes sleep apnea.

A person with excellent vascular health and normal eye anatomy likely carries a very different risk than someone with long-standing diabetes, hypertension, untreated sleep apnea, and a crowded optic nerve.

Established NAION risk factors include:

• Age over 50
• Type 2 diabetes
• Hypertension
• High cholesterol
• Smoking
• Cardiovascular or cerebrovascular disease
• Obstructive sleep apnea
• Small or crowded optic nerve anatomy, sometimes called “disc at risk”

Medical reviews describe NAION as the most common acute optic neuropathy in adults over 50. They also strongly associate it with hypertension, hypercholesterolemia, diabetes, cardiovascular disease, and obstructive sleep apnea.

The optic nerve anatomy matters because some people have a naturally crowded optic disc. In that setting, even mild swelling may create a pressure-like problem inside a tight space. This can worsen blood flow and injure the nerve.

Is NAION Reversible?

This is the hardest part of the discussion. NAION does not behave like simple eye strain, dry eye, or a temporary blur from fluctuating glucose. It involves injury to the optic nerve.

Some patients improve, especially in central vision. Others have persistent vision loss. Visual field defects often improve less reliably than central clarity. The North American Neuro-Ophthalmology Society notes that optic nerve swelling usually resolves within 1–2 months, but permanent optic nerve and vision changes may remain. It also notes that around 40% of people with significant central vision loss may improve over time, while visual field loss usually does not improve much.

A large clinical trial history also suggests mixed outcomes. Some patients regain vision lines, some worsen, and many remain relatively unchanged after the acute event resolves.

Therefore, the safest practical view is this: NAION may partially improve, but it is not reliably reversible. That is why sudden visual symptoms deserve immediate attention.

Can Anything Be Done to Prevent It?

There is no guaranteed prevention strategy. Still, a common-sense approach can reduce the broader vascular stress that contributes to NAION risk.

The goal is not to panic about the medication. The goal is to reduce the conditions that make the optic nerve more vulnerable.

A thoughtful prevention strategy includes:

• Treating sleep apnea, especially with consistent CPAP use when prescribed
• Avoiding smoking
• Controlling blood pressure without excessive nighttime drops
• Managing diabetes steadily rather than aggressively overcorrecting
• Treating high cholesterol and high triglycerides
• Staying hydrated during nausea, vomiting, or reduced intake
• Getting regular eye care when diabetes, retinopathy, or optic nerve concerns exist

The emphasis on steady rather than aggressive glucose correction matters here: a rapid drop in HbA1c can trigger transient microvascular shifts and alter perfusion around a tight optic disc.

Sleep apnea deserves special attention. NAION often occurs upon waking, and obstructive sleep apnea strongly links with NAION risk. Reviews recommend considering sleep evaluation in patients with NAION and addressing modifiable vascular risk factors. (NCBI)

Regulatory Safety Directive: European and UK health authorities explicitly advise that if a patient experiences sudden or rapid vision loss — even partial — while taking semaglutide, they must seek immediate, urgent ophthalmologic evaluation, and the medication should be discontinued if NAION is confirmed.

Who Should Think Twice Before Starting a GLP-1?

Most patients do not need to avoid GLP-1 therapy because of NAION concerns alone. The absolute risk appears very low, while the metabolic and cardiovascular benefits can be substantial. However, some patients deserve a deeper discussion before starting, especially if the concern is already present. These include patients with:

• Prior NAION in one eye
• Known crowded optic discs or “disc at risk” anatomy
• Unexplained optic nerve disease
• Active sudden or worsening visual symptoms
• Severe untreated sleep apnea
• Poorly controlled diabetes with significant diabetic retinopathy
• Multiple vascular risk factors that remain unmanaged
• A strong personal concern about vision risk after informed discussion

A prior NAION event deserves particular caution. About 15% of people with NAION in one eye may develop NAION in the other eye within 5 years, and diabetes may increase that risk.

This does not automatically mean every patient with prior NAION can never use a GLP-1 therapy. It means the decision should involve a careful risk-benefit discussion. In many cases, an ophthalmologist or neuro-ophthalmologist should help guide the decision.

Summary Table

Question	Balanced Answer
Is NAION common with GLP-1 therapy?	No. Current regulatory reviews describe it as very rare with semaglutide.
Is the risk zero?	No. Several studies suggest an association, especially with semaglutide.
Does association prove causation?	No. Diabetes, obesity, hypertension, and sleep apnea also raise baseline risk.
What symptoms matter most?	Sudden painless vision loss, cloudy vision, dim vision, or visual field loss in one eye.
Is it reversible?	Sometimes partially, but often not reliably.
Who needs extra caution?	Patients with prior NAION, optic nerve crowding, severe sleep apnea, or major vascular risk factors.

Patient Case Variations

• Case 1 — Low-Risk GLP-1 Candidate: A 42-year-old woman starts a GLP-1 therapy for obesity. She has no diabetes, no sleep apnea, no smoking history, and no known optic nerve disease. Her NAION risk remains very low. Weight loss improves blood pressure and metabolic markers, which may lower her broader vascular risk over time.
• Case 2 — Diabetes and Untreated Sleep Apnea: A 61-year-old man with type 2 diabetes, hypertension, high triglycerides, and loud snoring wants semaglutide. His risk comes less from one medication and more from the full vascular picture. A sleep study, CPAP treatment, blood pressure review, and eye exam create a smarter strategy before and during treatment.
• Case 3 — Prior NAION in One Eye: A 67-year-old woman lost partial vision from NAION 3 years ago. She now asks about GLP-1 therapy for diabetes and weight. This is not a routine start. Her care team reviews the benefit-risk balance and involves neuro-ophthalmology before making a final decision.
• Case 4 — Sudden Vision Change While on Semaglutide: A 56-year-old man wakes with a gray shadow in one eye. He does not wait for his next appointment. He seeks urgent ophthalmologic evaluation the same day. If NAION is confirmed, semaglutide should be stopped and vascular risk factors should be reassessed.
• Case 5 — Headline Anxiety Without Personal Risk Factors: A 49-year-old woman reads about NAION and becomes worried. She has obesity, mild insulin resistance, and rising blood pressure but no eye disease. A review shows that her absolute NAION risk remains very low, while her metabolic risk is more immediate. She proceeds with treatment and monitors for symptoms.

Takeaway

The GLP-1 and NAION discussion needs a balanced viewpoint. The concern appears real enough to respect, especially for semaglutide and especially in vulnerable patients. However, current evidence does not suggest that NAION is common among GLP-1 users. The best interpretation is that NAION remains a rare event, with risk shaped by the patient’s eye anatomy, vascular health, sleep apnea status, diabetes history, and overall metabolic condition.

At our practice in Montgomery County, Maryland, and through virtual care, we approach GLP-1 therapy through personalized, comprehensive care. We look at weight, glucose, blood pressure, cholesterol, sleep apnea, eye history, and long-term cardiovascular risk together. That broader context helps patients make thoughtful decisions without ignoring rare risks or losing sight of meaningful benefits.